Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
01 Maggio 2023 - 10:05PM
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a
clinical-stage biopharmaceutical company engaged in the discovery
and development of oral antiviral therapeutics for serious viral
diseases, today announced that it will host a live conference call
and audio webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report
financial results for the first quarter ended March 31, 2023, and
to provide a business update.
To access the live conference call, participants may register
here. The live audio webcast of the call will be available under
"Events and Presentations" in the Investor Relations section of the
Atea Pharmaceuticals website at ir.ateapharma.com. To participate
via telephone, please register in advance here. Upon registration,
all telephone participants will receive a confirmation email
detailing how to join the conference call, including the dial-in
number along with a unique passcode and registrant ID that can be
used to access the call. While not required, it is recommended that
participants join the call ten minutes prior to the scheduled
start. An archive of the audio webcast will be available on Atea
Pharmaceuticals’ website approximately two hours after the
conference call and will remain available for at least 90 days
following the event.
About Atea Pharmaceuticals
Atea is a clinical stage biopharmaceutical company focused on
discovering, developing and commercializing oral therapies to
address the unmet medical needs of patients with serious viral
infections. Leveraging the Company’s deep understanding of
antiviral drug development, nucleos(t)ide chemistry, biology,
biochemistry and virology, Atea is developing novel product
candidates to treat single stranded ribonucleic acid, or ssRNA,
viruses, which are a prevalent cause of serious viral diseases.
Atea plans to continue to build its pipeline of antiviral product
candidates through using its internal discovery capabilities
augmented by in-licensing. Currently, Atea is focused on the
development of orally-available antiviral agents for serious viral
infections, including severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C
virus (HCV). For more information, please visit
www.ateapharma.com.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the timing of Atea’s earnings call for the quarter ended
March 31, 2023. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to the
important factors discussed under the caption “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2022 and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate
Communications617-818-2985Barnes.jonae@ateapharma.com
Will O’ConnorStern Investor Relations
212-362-1200will.oconnor@sternir.com
Grafico Azioni Atea Pharmaceuticals (NASDAQ:AVIR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Atea Pharmaceuticals (NASDAQ:AVIR)
Storico
Da Giu 2023 a Giu 2024